Back HCV Treatment

EASL 2015: Liver Function and Survival Improve after Hepatitis C Treatment with Viekira Pak

Hepatitis C patients treated with AbbVie's Viekira Pak "3D" regimen saw improvements in liver function biomarkers, had better quality of life, and had increased survival compared to untreated people, according to mathematical model studies presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. One model showed that treatment can be cost-effective at all stages of liver disease.


Read more: